Breast Cancer Stamp Debuts in June
WASHINGTON--The US Postal Service will release its Breast Cancer Awareness stamp on June 15, in conjunction with the 1996 National Race for the Cure, the 5K race that raises money to fund breast cancer research, education, treatment, and screening.
WASHINGTON--The US Postal Service will release its Breast CancerAwareness stamp on June 15, in conjunction with the 1996 NationalRace for the Cure, the 5K race that raises money to fund breastcancer research, education, treatment, and screening.
Race for the Cure was founded by the Susan G. Komen Breast CancerFoundation, established in 1982 by Nancy Brinker in memory ofher sister Susan G. Komen, who died of breast cancer at the ageof 36.
Sale of the stamp will launch a 4-month public service campaignduring which the Postal Service will join with the YWCA's ENCOREplusprogram, the American Cancer Society, Lifetime Television, andseveral breast cancer groups in providing information and mammographyscreenings at neighborhood post offices and other community locations.
The NCI's Cancer Information Service toll-free number (1-800-4-CANCER)will be printed on the top border of each sheet of 20 stamps.One hundred million stamps will be printed.
Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer
October 30th 2023Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer
November 16th 2023Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
May 8th 2023Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.
